311 related articles for article (PubMed ID: 14751432)
1. Emotional withdrawal, CT abnormalities and drug response in late life depression.
Altamura AC; Bassetti R; Santini A; Frisoni GB; Mundo E
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):349-54. PubMed ID: 14751432
[TBL] [Abstract][Full Text] [Related]
2. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
3. Effects of pharmacological therapy on gait and cognitive function in depressed patients.
Paleacu D; Shutzman A; Giladi N; Herman T; Simon ES; Hausdorff JM
Clin Neuropharmacol; 2007; 30(2):63-71. PubMed ID: 17414938
[TBL] [Abstract][Full Text] [Related]
4. Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home.
Roose SP; Nelson JC; Salzman C; Hollander SB; Rodrigues H;
Curr Med Res Opin; 2003; 19(8):737-46. PubMed ID: 14687445
[TBL] [Abstract][Full Text] [Related]
5. Adverse effects of depression and cognitive impairment on rehabilitation participation and recovery from hip fracture.
Lenze EJ; Munin MC; Dew MA; Rogers JC; Seligman K; Mulsant BH; Reynolds CF
Int J Geriatr Psychiatry; 2004 May; 19(5):472-8. PubMed ID: 15156549
[TBL] [Abstract][Full Text] [Related]
6. The effect of alexithymic features on response to antidepressant medication in patients with major depression.
Ozsahin A; Uzun O; Cansever A; Gulcat Z
Depress Anxiety; 2003; 18(2):62-6. PubMed ID: 12964172
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of milnacipran on cognitive dysfunction with post-stroke depression: preliminary open-label study.
Sato S; Yamakawa Y; Terashima Y; Ohta H; Asada T
Psychiatry Clin Neurosci; 2006 Oct; 60(5):584-9. PubMed ID: 16958942
[TBL] [Abstract][Full Text] [Related]
8. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
[TBL] [Abstract][Full Text] [Related]
9. White matter hyperintensities and chronicity of depression.
Heiden A; Kettenbach J; Fischer P; Schein B; Ba-Ssalamah A; Frey R; Naderi MM; Gulesserian T; Schmid D; Trattnig S; Imhof H; Kasper S
J Psychiatr Res; 2005 May; 39(3):285-93. PubMed ID: 15725427
[TBL] [Abstract][Full Text] [Related]
10. Depression in methadone maintenance treatment patients: rate and risk factors.
Peles E; Schreiber S; Naumovsky Y; Adelson M
J Affect Disord; 2007 Apr; 99(1-3):213-20. PubMed ID: 17055063
[TBL] [Abstract][Full Text] [Related]
11. Hypofrontality and negative symptoms in patients with dementia of Alzheimer type.
Galynker II; Dutta E; Vilkas N; Ongseng F; Finestone H; Gallagher R; Serseni D; Rosenthal RN
Neuropsychiatry Neuropsychol Behav Neurol; 2000 Jan; 13(1):53-9. PubMed ID: 10645737
[TBL] [Abstract][Full Text] [Related]
12. Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study.
Varia I; Venkataraman S; Hellegers C; Gersing K; Doraiswamy PM
Psychopharmacol Bull; 2007; 40(1):47-56. PubMed ID: 17285095
[TBL] [Abstract][Full Text] [Related]
13. [Depressive symptomatology and sleep apnea syndrome].
Pochat MD; Ferber C; Lemoine P
Encephale; 1993; 19(6):601-7. PubMed ID: 12404778
[TBL] [Abstract][Full Text] [Related]
14. Differences in the behavioral and psychological symptoms between Alzheimer's disease and vascular dementia: are the different pharmacologic treatment strategies justifiable?
Kim JM; Lyons D; Shin IS; Yoon JS
Hum Psychopharmacol; 2003 Apr; 18(3):215-20. PubMed ID: 12672174
[TBL] [Abstract][Full Text] [Related]
15. Treatment response and cognitive impairment in major depression: association with C-reactive protein.
Chang HH; Lee IH; Gean PW; Lee SY; Chi MH; Yang YK; Lu RB; Chen PS
Brain Behav Immun; 2012 Jan; 26(1):90-5. PubMed ID: 21839826
[TBL] [Abstract][Full Text] [Related]
16. Mood and neuropsychological changes in women with midlife depression treated with escitalopram.
Wroolie TE; Williams KE; Keller J; Zappert LN; Shelton SD; Kenna HA; Reynolds MF; Rasgon NL
J Clin Psychopharmacol; 2006 Aug; 26(4):361-6. PubMed ID: 16855452
[TBL] [Abstract][Full Text] [Related]
17. Assessing depression outcome in patients with moderate dementia: sensitivity of the HoNOS65+ scale.
Canuto A; Rudhard-Thomazic V; Herrmann FR; Delaloye C; Giannakopoulos P; Weber K
J Neurol Sci; 2009 Aug; 283(1-2):69-72. PubMed ID: 19261298
[TBL] [Abstract][Full Text] [Related]
18. Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women.
Pae CU; Mandelli L; Han C; Ham BJ; Masand PS; Patkar AA; Steffens DC; De Ronchi D; Serretti A
Neuro Endocrinol Lett; 2008 Aug; 29(4):500-6. PubMed ID: 18766158
[TBL] [Abstract][Full Text] [Related]
19. Mood disorders after stroke: diagnostic validation of the poststroke depression rating scale.
Quaranta D; Marra C; Gainotti G
Cerebrovasc Dis; 2008; 26(3):237-43. PubMed ID: 18648195
[TBL] [Abstract][Full Text] [Related]
20. Symptoms of anxiety in depression: assessment of item performance of the Hamilton Anxiety Rating Scale in patients with depression.
Vaccarino AL; Evans KR; Sills TL; Kalali AH
Depress Anxiety; 2008; 25(12):1006-13. PubMed ID: 18800370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
